Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label extension study of LCZ696 monotherapy and LCZ696 + amlodipine in essential hypertension
2013-002306-31Phase 3Completed
- Sponsor
- Novartis
- Start
- Nov 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of sacubitril + valsartan and amlodipine in essential hypertension (2 arms), sponsored by Novartis. Started Nov 2013; status: completed.
02
Drugs
sacubitril + valsartanamlodipine
03
Conditions
essential hypertension
Beyond the preview
Go deeper on 2013-002306-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002306-31.